Angle PLC Announces Posting of 2023 Annual Report & Notice of the AGM
Angle PLC Announces Posting of 2023 Annual Report & Notice of the AGM
ANGLE plcGUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2023, and the Notice of Annual General Meeting within it, have been posted to shareholders, and are available on the Company's website.
ANGLE plc（“該公司”）（AIM：AGL）（OTCQX：ANPCY）是一家領先的液體活檢公司，爲研究、藥物開發和臨床腫瘤學提供創新的循環腫瘤細胞（CTC）解決方案。宣佈了截至2023年12月31日的審計年度報告和財務報表，以及其中的年度股東大會通知，已經寄給股東，並可通過公司網站查看。
The Annual General Meeting will now be held at 12:00 pm on Thursday 11 July 2024 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded.
年度股東大會現已確定於2024年7月11日星期四中午12:00在Surrey Technology Centre，Surrey Research Park，Guildford，Surrey GU2 7YG舉行。董事會期待親自歡迎股東，並在會議程序結束後提供業務更新。
For further information:
進一步了解：
ANGLE plc |
+44 (0) 1483 343434 |
Andrew Newland, Chief Executive |
|
Berenberg (NOMAD and Broker) |
+44 (0) 20 3207 7800 |
FTI Consulting |
+44 (0) 203 727 1000 |
ANGLE plc |
+44（0）1483 343434 |
Andrew Newland，首席執行官 |
|
Berenberg（NOMAD和經紀人） |
+44（0）20 3207 7800 |
fti諮詢 |
+44（0）203 727 1000 |
Notes for editors
編輯註釋
About ANGLE plc
關於ANGLE Plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix PC1 system enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE是一家領先的液體活檢公司，爲研究、藥物開發和臨床腫瘤學提供創新的循環腫瘤細胞（CTC）解決方案，可以使用簡單的血液樣本。 ANGLE的FDA批准和受保護的循環腫瘤細胞（CTC）收穫技術稱爲Parsortix PC1系統，使得對樣本的完整下游分析包括整個細胞成像和蛋白組分析以及全基因組和轉錄組分子分析成爲可能。ANGLE的商業業務專注於診斷產品和臨床服務。 診斷產品包括Parsortix系統和相關消耗品。 通過ANGLE在英國的符合GCP的實驗室提供臨床服務業務。 這些服務包括爲製藥業定製的測定開發和臨床試驗測試。 Parsortix系統的超過90篇同行評議的出版物證明了其表現。 欲了解更多信息，請訪問
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK. Services include custom made assay development and clinical trial testing for pharma.
Parsortix系統ANGLE的GCP合規實驗室通過提供實驗室和臨床試驗測試提供臨床服務業務。這些服務包括爲製藥業定製的測定開發和臨床試驗測試。
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit
超過90篇同行評議的出版物證明了Parsortix系統的性能。 欲了解更多信息，請訪問
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit .
此信息由英國證券交易所的新聞服務RNS提供。RNS獲批由英國金融行爲監管局擔任英國主要信息提供者。有關使用和分發此信息的條款和條件可能適用。欲了解更多信息，請聯繫rns@lseg.com或訪問。
SOURCE: ANGLE plc
來源：ANGLE plc
譯文內容由第三人軟體翻譯。
